Charles River Laboratories Intl. Inc (NYSE:CRL) insider Davide Molho sold 11,717 shares of the stock in a transaction on Thursday, March 16th. The shares were sold at an average price of $90.00, for a total transaction of $1,054,530.00. Following the completion of the transaction, the insider now directly owns 28,266 shares in the company, valued at $2,543,940. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of Charles River Laboratories Intl. Inc (NYSE:CRL) traded down 0.74% on Monday, reaching $89.33. 127,926 shares of the company’s stock traded hands. The stock has a market capitalization of $4.23 billion, a PE ratio of 27.69 and a beta of 0.99. The company has a 50 day moving average of $86.28 and a 200-day moving average of $80.06. Charles River Laboratories Intl. Inc has a 52 week low of $67.20 and a 52 week high of $91.57.

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings results on Tuesday, February 14th. The company reported $1.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.11 by $0.10. The firm had revenue of $466.80 million for the quarter, compared to analysts’ expectations of $441.64 million. Charles River Laboratories Intl. had a net margin of 9.05% and a return on equity of 25.75%. The firm’s quarterly revenue was up 31.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.00 earnings per share. Equities research analysts forecast that Charles River Laboratories Intl. Inc will post $5.06 earnings per share for the current year.

Insider Buying and Selling by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Your IP Address:

A number of research analysts recently commented on the stock. Jefferies Group LLC reaffirmed a “buy” rating on shares of Charles River Laboratories Intl. in a research report on Thursday. Barclays PLC raised shares of Charles River Laboratories Intl. from an “underweight” rating to an “equal weight” rating and increased their target price for the company from $65.00 to $77.00 in a research report on Wednesday, November 30th. Goldman Sachs Group Inc raised shares of Charles River Laboratories Intl. from a “sell” rating to a “neutral” rating and increased their target price for the company from $75.00 to $77.00 in a research report on Friday, December 16th. They noted that the move was a valuation call. Finally, Evercore ISI raised shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $86.50 target price on the stock in a research report on Wednesday, January 4th. Six analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $85.95.

A number of hedge funds have recently bought and sold shares of the stock. Quantbot Technologies LP boosted its stake in Charles River Laboratories Intl. by 291.7% in the third quarter. Quantbot Technologies LP now owns 1,414 shares of the company’s stock valued at $117,000 after buying an additional 1,053 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in Charles River Laboratories Intl. by 41.8% in the fourth quarter. Envestnet Asset Management Inc. now owns 1,785 shares of the company’s stock valued at $135,000 after buying an additional 526 shares in the last quarter. Bessemer Group Inc. boosted its stake in Charles River Laboratories Intl. by 2.3% in the fourth quarter. Bessemer Group Inc. now owns 1,933 shares of the company’s stock valued at $147,000 after buying an additional 43 shares in the last quarter. Tower Research Capital LLC TRC bought a new stake in Charles River Laboratories Intl. during the third quarter valued at about $181,000. Finally, Tyers Asset Management LLC bought a new stake in Charles River Laboratories Intl. during the fourth quarter valued at about $188,000. 95.32% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

5 Day Chart for NYSE:CRL

Receive News & Ratings for Charles River Laboratories Intl. Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. Inc and related companies with MarketBeat.com's FREE daily email newsletter.